TEL AVIV, Israel, June 20, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics, a clinical-stage biotechnology company committed to the development of first-in-class treatments for immune-inflammatory diseases and cancer, today announced that it has completed enrollment of two Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound VB-201 in psoriasis and ulcerative colitis. A total of 194 patients with psoriasis and of 112 patients with ulcerative colitis were enrolled in the study. The Company expects to report top line results from each of the studies in the first quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.
